HC Wainwright Predicts Disc Medicine FY2030 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Disc Medicine in a research report issued to clients and investors on Monday, January 26th. HC Wainwright analyst D. Tsao expects that the company will earn $8.37 per share for the year. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Several other research analysts have also weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, January 21st. Wells Fargo & Company boosted their target price on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Truist Financial upped their price target on shares of Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Stifel Nicolaus assumed coverage on shares of Disc Medicine in a research report on Monday, November 3rd. They issued a “buy” rating and a $125.00 price objective for the company. Finally, Raymond James Financial reaffirmed a “market perform” rating on shares of Disc Medicine in a report on Thursday, January 15th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus price target of $119.45.

Disc Medicine Price Performance

NASDAQ:IRON opened at $82.14 on Tuesday. The stock’s 50-day simple moving average is $83.99 and its 200 day simple moving average is $73.74. Disc Medicine has a 52-week low of $30.82 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The company has a market cap of $3.10 billion, a P/E ratio of -15.35 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.29).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Disc Medicine by 36.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after purchasing an additional 490 shares during the period. KBC Group NV bought a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $80,000. Aberdeen Group plc grew its position in Disc Medicine by 631.0% during the fourth quarter. Aberdeen Group plc now owns 234,358 shares of the company’s stock worth $18,610,000 after buying an additional 202,297 shares in the last quarter. Avanza Fonder AB increased its stake in Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after acquiring an additional 235 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Disc Medicine by 161.9% in the 4th quarter. SG Americas Securities LLC now owns 21,122 shares of the company’s stock valued at $1,677,000 after acquiring an additional 13,058 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Insider Transactions at Disc Medicine

In related news, insider William Jacob Savage sold 13,093 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total value of $1,194,343.46. Following the transaction, the insider directly owned 75,702 shares in the company, valued at approximately $6,905,536.44. This represents a 14.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rahul Khara sold 6,500 shares of Disc Medicine stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $78.69, for a total transaction of $511,485.00. Following the completion of the sale, the insider owned 37,793 shares of the company’s stock, valued at $2,973,931.17. This trade represents a 14.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 275,470 shares of company stock worth $24,966,170. 3.64% of the stock is currently owned by company insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.